{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+Cancers&page=31", "query": { "condition": "Kidney Cancers", "page": 31 }, "page_size": 10 }, "pagination": { "page": 31, "page_size": 10, "total_count": 1818, "total_pages": 182, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+Cancers&page=32&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+Cancers&page=30&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T18:58:43.900Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04115254", "title": "Stereotactic Magnetic Resonance Guided Radiation Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pancreas Cancer", "Lung Cancer", "Renal Cancer", "Adrenal Metastases", "Prostate Cancer", "Liver Metastases", "Oligoprogressive Nodal Metastases", "Metachronous Nodal Metastases", "Synchronous Nodal Metastases", "Mesothelioma", "Spine Metastases", "Brain Metastases", "Borderline Resectable Pancreatic Carcinoma" ], "interventions": [ { "name": "MR-guided Linac", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 397, "start_date": "2019-10-22", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2025-11-13", "last_synced_at": "2026-11-15T18:58:43.900Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04115254" }, { "nct_id": "NCT02452554", "title": "Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pleuropulmonary Blastoma", "Recurrent Malignant Peripheral Nerve Sheath Tumor", "Recurrent Neuroblastoma", "Recurrent Rhabdomyosarcoma", "Recurrent Synovial Sarcoma", "Wilms Tumor" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lorvotuzumab Mertansine", "type": "BIOLOGICAL" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "30 Years", "sex": "ALL", "summary": "12 Months to 30 Years" }, "enrollment_count": 62, "start_date": "2015-10-12", "completion_date": "2021-09-30", "has_results": true, "last_update_posted_date": "2022-01-13", "last_synced_at": "2026-11-15T18:58:43.900Z", "location_count": 69, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 60 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02452554" }, { "nct_id": "NCT07179770", "title": "Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "Belzutifan", "type": "DRUG" }, { "name": "89Zr-DFO-girentuximab", "type": "DRUG" }, { "name": "89Zr-DFO-girentuximab PET", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2025-09-15", "completion_date": "2028-10-01", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-11-15T18:58:43.900Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07179770" }, { "nct_id": "NCT05678673", "title": "Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "XL092", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 317, "start_date": "2023-01-01", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-11-15T18:58:43.900Z", "location_count": 10, "location_summary": "Duarte, California • Newport Beach, California • San Francisco, California + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05678673" }, { "nct_id": "NCT02950766", "title": "NeoVax Plus Ipilimumab in Renal Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "NeoVax", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Patrick Ott, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2019-03-03", "completion_date": "2030-05-30", "has_results": false, "last_update_posted_date": "2026-02-03", "last_synced_at": "2026-11-15T18:58:43.900Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02950766" }, { "nct_id": "NCT01808079", "title": "Gene Analysis in Studying Susceptibility to Wilms Tumor", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Recurrent Childhood Kidney Neoplasm", "Stage I Kidney Wilms Tumor", "Stage II Kidney Wilms Tumor", "Stage III Kidney Wilms Tumor", "Stage IV Kidney Wilms Tumor" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1, "start_date": "2009-10", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2016-08-22", "last_synced_at": "2026-11-15T18:58:43.900Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01808079" }, { "nct_id": "NCT00001803", "title": "Von Hippel-Lindau Disease Genetic Epidemiology Study", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Von Hippel Lindau Disease", "Kidney Neoplasms" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "13 Years to 100 Years" }, "enrollment_count": 546, "start_date": "1999-02-26", "completion_date": "2020-01-09", "has_results": false, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-11-15T18:58:43.900Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001803" }, { "nct_id": "NCT04398368", "title": "Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage 0a Renal Pelvis and Ureter Cancer AJCC v8", "Stage 0a Renal Pelvis Cancer AJCC v8", "Stage 0a Ureter Cancer AJCC v8", "Stage 0is Renal Pelvis and Ureter Cancer AJCC v8", "Stage 0is Renal Pelvis Cancer AJCC v8", "Stage 0is Ureter Cancer AJCC v8", "Stage I Renal Pelvis and Ureter Cancer AJCC v8", "Stage I Renal Pelvis Cancer AJCC v8", "Stage I Ureter Cancer AJCC v8", "Stage II Renal Pelvis and Ureter Cancer AJCC v8", "Stage II Renal Pelvis Cancer AJCC v8", "Stage II Ureter Cancer AJCC v8", "Stage III Renal Pelvis and Ureter Cancer AJCC v8", "Stage III Renal Pelvis Cancer AJCC v8", "Stage III Ureter Cancer AJCC v8", "Stage IV Renal Pelvis and Ureter Cancer AJCC v8", "Stage IV Renal Pelvis Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8" ], "interventions": [ { "name": "Gemcitabine Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2020-06-05", "completion_date": "2023-02-02", "has_results": true, "last_update_posted_date": "2023-08-08", "last_synced_at": "2026-11-15T18:58:43.900Z", "location_count": 4, "location_summary": "Jacksonville, Florida • Rochester, Minnesota • Winston-Salem, North Carolina + 1 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04398368" }, { "nct_id": "NCT05360680", "title": "A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Gastric Cancer", "Pancreatic Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "CUE-102", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cue Biopharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2022-06-14", "completion_date": "2025-03-12", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-11-15T18:58:43.900Z", "location_count": 15, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05360680" }, { "nct_id": "NCT00043368", "title": "PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Breast Neoplasms", "Carcinoma, Renal Cell", "Lymphoma, T-Cell", "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "PF-3512676", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2002-09", "completion_date": "2007-06", "has_results": false, "last_update_posted_date": "2009-03-12", "last_synced_at": "2026-11-15T18:58:43.900Z", "location_count": 31, "location_summary": "Berkely, California • Gilroy, California • Hollister, California + 23 more", "locations": [ { "city": "Berkely", "state": "California" }, { "city": "Gilroy", "state": "California" }, { "city": "Hollister", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00043368" } ] }